Piqray is a drug owned by Novartis Pharmaceuticals Corp. It is protected by 2 US drug patents filed in 2019 out of which none have expired yet. Piqray's patents have been open to challenges since 25 May, 2023. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 29, 2033. Details of Piqray's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8227462 | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(7 years from now) | Active |
| US8476268 | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Piqray's patents.
Latest Legal Activities on Piqray's Patents
Given below is the list of recent legal activities going on the following patents of Piqray.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Jan, 2024 | US8227462 |
| Electronic Review Critical | 29 May, 2023 | US8227462 |
| Patent Term Extension Certificate Critical | 22 May, 2023 | US8227462 |
| Notice of Final Determination -Eligible | 18 Oct, 2022 | US8227462 |
| Withdrawal of Application for PTE Critical | 02 Sep, 2022 | US8476268 |
| Notice of Final Determination -Election Required | 01 Aug, 2022 | US8476268 |
| Notice of Final Determination -Election Required | 01 Aug, 2022 | US8227462 |
| FDA Final Eligibility Letter Critical | 03 Mar, 2022 | US8227462 |
| FDA Final Eligibility Letter Critical | 03 Mar, 2022 | US8476268 |
| transaction for FDA Determination of Regulatory Review Period | 08 Jul, 2021 | US8476268 |
FDA has granted several exclusivities to Piqray. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Piqray, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Piqray.
Exclusivity Information
Piqray holds 2 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Piqray's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| New Indication(I-937) | Jan 18, 2027 |
US patents provide insights into the exclusivity only within the United States, but Piqray is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Piqray's family patents as well as insights into ongoing legal events on those patents.
Piqray's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Piqray's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 29, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Piqray Generics:
There are no approved generic versions for Piqray as of now.
Alternative Brands for Piqray
Piqray which is used for treating HR-positive, HER-2-negative, PIK3CA-mutated advanced or metastatic breast cancer in combination with fulvestrant., has several other brand drugs using the same active ingredient (Alpelisib). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Novartis |
|
About Piqray
Piqray is a drug owned by Novartis Pharmaceuticals Corp. It is used for treating HR-positive, HER-2-negative, PIK3CA-mutated advanced or metastatic breast cancer in combination with fulvestrant. Piqray uses Alpelisib as an active ingredient. Piqray was launched by Novartis in 2019.
Approval Date:
Piqray was approved by FDA for market use on 24 May, 2019.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Piqray is 24 May, 2019, its NCE-1 date is estimated to be 25 May, 2023.
Active Ingredient:
Piqray uses Alpelisib as the active ingredient. Check out other Drugs and Companies using Alpelisib ingredient
Treatment:
Piqray is used for treating HR-positive, HER-2-negative, PIK3CA-mutated advanced or metastatic breast cancer in combination with fulvestrant.
Dosage:
Piqray is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG | TABLET | Prescription | ORAL |
| 150MG | TABLET | Prescription | ORAL |
| 200MG | TABLET | Prescription | ORAL |